Abstract:Objective: Metabolic fatty liver disease drives chronic liver injury leading to fibrosis. This study aimed to establish a model utilising serum circulating fibroblast activation protein (cFAP) to diagnose advanced fibrosis in patients with fatty liver disease. Design: Two retrospective cohorts recruited from tertiary hepatology clinics were studied as training (n=160) and external validation cohorts (n=342), with prevalence of histologic advanced fibrosis (F3/F4) of 20% and 11%, respectively. A marker of activated mesenchymal fibrogenic cells, cFAP, was measured using our single-step enzyme assay. A predictive model, FAP Index, containing age, type 2 diabetes, alanine transaminase and ordinal cFAP was developed using logistic regression. Diagnostic accuracy of FAP Index was assessed on a single and then sequential basis. Results: FAP Index AUROC was 0.875 (95% CI 0.813-0.938) in the training cohort and 0.841 (95% CI 0.776-0.906) in the validation cohort. Low cut-off -1.68 (Sensitivity 80.0%, negative predictive value 95.5%) and high cut-off +0.953 values (Specificity 97.7%, positive predictive value 88.9%) excluded and diagnosed advanced fibrosis, respectively. In the validation cohort, FAP Index then FIB-4 reduced indeterminate results by one-third compared to FIB-4 alone. Whereas FAP-Index followed by NFS (NAFLD Fibrosis Score) resulted in a reduction of indeterminate results by 70% compared to NFS alone. Conclusion: FAP Index is a novel, rapid, robust, inexpensive diagnostic tool for advanced fibrosis in metabolic fatty liver disease. Applying FAP Index followed by FIB-4 or NFS facilitates accurate risk-stratification of patients by greatly reducing the frequency of indeterminate results compared to FIB-4 or NFS alone, without compromising negative predictive value.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to improve the accuracy of fibrosis risk stratification in the population with Metabolic Fatty Liver Disease (MFLD). Specifically, the study aims to develop a predictive model - the FAP index, which is based on serum circulating fibroblast activation protein (cFAP), to diagnose advanced fibrosis in MFLD patients. ### Background - **Metabolic Fatty Liver Disease**: It affects approximately one - quarter of the global population and is mainly caused by factors such as abnormal lipid metabolism, disordered blood - glucose regulation, changes in the gut microbiota, and genetic variations. These physiological abnormalities lead to chronic inflammation, which in turn causes liver fibrosis and may eventually lead to end - stage liver disease and hepatocellular carcinoma. - **Limitations of current screening methods**: Currently commonly used screening algorithms (such as FIB - 4 and NAFLD Fibrosis Score, NFS) have certain uncertain results in patients at high risk of advanced fibrosis and require further expensive tests. ### Research objectives - **Develop the FAP index**: Use cFAP enzyme activity measurement and routine clinical variables (such as age, type 2 diabetes, alanine aminotransferase level) to establish a fast, robust, and low - cost diagnostic tool. - **Verify the effectiveness of the FAP index**: Evaluate the diagnostic accuracy of the FAP index through the training cohort and the external validation cohort, and compare it with existing screening methods (FIB - 4 and NFS). ### Main findings - **Diagnostic accuracy of the FAP index**: - In the training cohort, the AUROC of the FAP index is 0.875 (95% CI: 0.813 - 0.938). - In the validation cohort, the AUROC of the FAP index is 0.841 (95% CI: 0.776 - 0.906). - **Cut - off values of the FAP index**: - The low cut - off value is - 1.68 (sensitivity 80.0%, negative predictive value 95.5%). - The high cut - off value is 0.953 (specificity 97.7%, positive predictive value 88.9%). - **Reduce uncertain results**: - In the validation cohort, FIB - 4 can reduce one - third of the uncertain results after using the FAP index. - After using the FAP index, NFS can reduce 70% of the uncertain results. ### Conclusions - **Advantages of the FAP index**: - It is a new, fast, robust, and low - cost diagnostic tool for advanced fibrosis. - Compared with using FIB - 4 or NFS alone, the FAP index can significantly reduce uncertain results without reducing the negative predictive value. - It can be adapted to point - of - care or reflex test settings to achieve low - cost and high - throughput FAP index screening. ### Potential impacts - **Clinical practice**: With the approval of drug treatments for fatty liver disease, improved risk - stratification tools have become particularly important. The use of the FAP index can reduce unnecessary tertiary referrals and further tests and improve screening efficiency. - **Research and policy**: The development and application of the FAP index may have an important impact on the research, clinical practice, and policy - making of fatty liver disease, especially in community screening. Through these findings, this study provides a new and more effective tool for screening advanced fibrosis in patients with Metabolic Fatty Liver Disease.

Development and validation of a novel circulating fibroblast activation protein - based predictive model to improve fibrosis risk stratification in metabolic liver disease population

Development and validation of a novel score for fibrosis staging in patients with chronic hepatitis B.

A Novel Model for Detecting Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.

MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic‐associated fatty liver disease

Metabolic Disorders Combined with Noninvasive Tests to Screen Advanced Fibrosis in Nonalcoholic Fatty Liver Disease

A Novel Non-Invasive Model for the Prediction of Advanced Liver Fibrosis in Chronic Hepatitis B Patients with NAFLD.

Dynamic Changes of Key Metabolites During Liver Fibrosis in Rats.

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

Diagnosis of Fibrosis Using Blood Markers and Logistic Regression in Southeast Asian Patients With Non-alcoholic Fatty Liver Disease

Step Layered Combination of Noninvasive Fibrosis Models Improves Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease.

Development and Validation of a Non-Invasive Model for Predicting Liver Cirrhosis in Patients with Chronic Hepatitis B

Automated Fibrosis-4 Index: Simplifying Non-Alcoholic Fatty Liver Disease for Diabetologists

Incremental value of blood-based markers of liver fibrosis in cardiovascular risk stratification

Maf-5 Predicts Liver Fibrosis Risk And Outcome In The General Population With Metabolic Dysfunction

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study

Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis.

The fibrosis investigating navigator in diabetes (FIND): A tool to predict liver fibrosis risk in subjects with diabetes

Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis

Comparison of blood-based liver fibrosis scores in the Mount Sinai Health System, MASLD Registry, and NHANES 2017-2020 study

Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development